Navigation Links
Annual Meeting of the Consortium of Multiple Sclerosis Centers,Focuses on the Challenges of Care and Research in Multiple,Sclerosis

WASHINGTON, June 01, 2007 /PRNewswire/ -- The annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC), the largest meeting devoted to the comprehensive care and science of multiple sclerosis (MS), is underway in the nation's capital today. Multiple sclerosis, a disease of the central nervous system that affects 400,000 people in the United States, challenges patients, care partners and healthcare professionals in many ways. The meeting provides specialists in the fields of MS healthcare, research, advocacy, community service and education to keep abreast of the latest information on patient care delivery systems and evidence-based practice.

Below are three highlights from the conference that reflect the caliber of innovation and inspiration at the meeting.

    1. Dr. Randall T. Schapiro was honored with a Lifetime Achievement Award

       by the CMSC on May 31st.  This award recognizes the accomplishments of

       leading figures in MS care and research for their contributions to the

       CMSC.  Dr. Schapiro founded the first comprehensive MS center in the

       United States, the Fairview MS Center in Minneapolis, which he

       continues to direct.  A founder and past-president of the CMSC and a

       member of the Board of Trustees of the CMSC Foundation, he serves on

       the boards of the International MS Society and the National MS

       Society.


       "Dr. Schapiro is much beloved by his patients," said June

       Halper, Executive Director of the CMSC.  "He has dedicated his life to

       the service of people with MS.  His innovative MS program includes

       everything from the first MS Achievement Center, coordinated rehab

       services, home care services, outpatient and inpatient care, to

       education and research."


    2. A web-based program was premiered on May 31st on the latest strategies

       for treating MS-related spasticity, a very difficult symptom of the

       disease. 
 It includes discussions on non-pharmaceutical strategies and

       assessments, medication management, rehabilitation, and for some

       instances, intrathecal delivery of baclofen, a technology that has

       revolutionized rehabilitation in MS.  Developed by a team on behalf of

       the CMSC, headed by Dr. Francois Bethoux, Danni Gogol, RN, and Matt

       Sutliff, physical therapist, it will be featured on the CMSC website

       after the launch.  The development of this program was a CMSC project

       partially supported by Medtronic, Inc.


    3. Numerous presentations throughout the week will focus on new and

       important information about MS research.  A new feature of CMSC

       includes a "late breaking" poster session on June 1st in which Dr. Mark

       S. Freedman, Professor of Neurology at the University of Ottawa, will

       share results from a study that validates that immediate treatment of

       early stages of MS with an immunomodulatory agent can significantly

       slow the onset of disability.

Dr. Freedman is an investigator of the study called BENEFIT (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment) that tested whether earlier stages of MS can also benefit from pharmaceutical intervention. Results showed that prompt initiation of Betaseron treatment in patients with a first MS attack was associated with a 40 percent reduced risk of confirmed disability progression over three years. This study confirms that early treatment is desirable in MS to avoid or diminish long-term disability. Betaseron is approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. Patients with MS in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with MS.

For information about the Consortium of Multiple Sclerosis Centers, please visit http://www.mscare.org/cmsc/

CONTACT: June Halper, Executive Director of the CMSC, june.halper@mscare.org

Web site: http://www.mscare.org/cmsc/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
5. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
6. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
7. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
8. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
9. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):